ALSO IN THIS MONTH'S ISSUE

• Against All Odds: Advancing From R&D To Phase 3

  There is nothing more rewarding than knowing that we can help save a life and give hope to patients and their friends and families. Because lives are at stake, there must be more regulations and processes to ensure safety and efficacy.

• Coming Out Of Stealth Mode: What To Know And Do

  Five CEOs discuss their experiences with stealth mode transitions. They address when and how a company should turn away from that introspective state and show itself to the world.

• The Collective Benefits Of A Collaborative CFO

  Terry Coelho, CFO, works as a team member, not just a finance manager, at BioDelivery Sciences.

• From Fusion Energy To Med Device … To Drug Developer?

  TAE Life Sciences wanted to create a combination product that brought together its neutron beam with a drug that delivers boron to cancer cells. But, the company didn’t want to be in a position where it relied on another company for the drug needed.